Your browser doesn't support javascript.
COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.
Mazagatos, Clara; Delgado-Sanz, Concepción; Monge, Susana; Pozo, Francisco; Oliva, Jesús; Sandonis, Virginia; Gandarillas, Ana; Quiñones-Rubio, Carmen; Ruiz-Sopeña, Cristina; Gallardo-García, Virtudes; Basile, Luca; Barranco-Boada, María Isabel; Hidalgo-Pardo, Olga; Vazquez-Cancela, Olalla; García-Vázquez, Miriam; Fernández-Sierra, Amelia; Milagro-Beamonte, Ana; Ordobás, María; Martínez-Ochoa, Eva; Fernández-Arribas, Socorro; Lorusso, Nicola; Martínez, Ana; García-Fulgueiras, Ana; Sastre-Palou, Bartolomé; Losada-Castillo, Isabel; Martínez-Cuenca, Silvia; Rodríguez-Del Águila, Mar; Latorre, Miriam; Larrauri, Amparo.
  • Mazagatos C; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Delgado-Sanz C; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Monge S; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Pozo F; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Oliva J; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Sandonis V; Consortium for Biomedical Research in Infectious Diseases (CIBERINFEC), Madrid, Spain.
  • Gandarillas A; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Quiñones-Rubio C; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.
  • Ruiz-Sopeña C; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Gallardo-García V; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Basile L; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.
  • Barranco-Boada MI; Subdirección General de Epidemiología, Dirección General de Salud Pública, Madrid, Spain.
  • Hidalgo-Pardo O; Servicio de Epidemiología y Prevención Sanitaria, Dirección General de Salud Pública, Consumo y Cuidados, Logroño, Spain.
  • Vazquez-Cancela O; Dirección General de Salud Pública, Junta de Castilla y León, Valladolid, Spain.
  • García-Vázquez M; Dirección General de Salud Pública y Ordenación Farmacéutica, Junta de Andalucía, Seville, Spain.
  • Fernández-Sierra A; Subdirección General de Vigilancia y Respuesta a Emergencias de Salud Pública, Agencia de Salud Pública, Catalonia, Spain.
  • Milagro-Beamonte A; Servicio de Epidemiología, Dirección General de Salud Pública, Consejería de Salud, Murcia, Spain.
  • Ordobás M; Servicio de Medicina Preventiva Hospital Universitario Son Espases, Servicio de Epidemiología, Consellería de Salut, Palma, Spain.
  • Martínez-Ochoa E; Servicio de Medicina Preventiva, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
  • Fernández-Arribas S; Vigilancia Epidemiológica, Dirección General de Salud Pública, Departamento de Sanidad, Gobierno de Aragón, Zaragoza, Spain.
  • Lorusso N; Servicio Medicina Preventiva, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Martínez A; Laboratorio de Microbiología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • García-Fulgueiras A; Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain.
  • Sastre-Palou B; Subdirección General de Epidemiología, Dirección General de Salud Pública, Madrid, Spain.
  • Losada-Castillo I; Servicio de Epidemiología y Prevención Sanitaria, Dirección General de Salud Pública, Consumo y Cuidados, Logroño, Spain.
  • Martínez-Cuenca S; Dirección General de Salud Pública, Junta de Castilla y León, Valladolid, Spain.
  • Rodríguez-Del Águila M; Dirección General de Salud Pública y Ordenación Farmacéutica, Junta de Andalucía, Seville, Spain.
  • Latorre M; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Larrauri A; Subdirección General de Vigilancia y Respuesta a Emergencias de Salud Pública, Agencia de Salud Pública, Catalonia, Spain.
Influenza Other Respir Viruses ; 16(6): 1014-1025, 2022 11.
Article in English | MEDLINE | ID: covidwho-1956749
ABSTRACT

BACKGROUND:

With the emergence of SARS-CoV-2, influenza surveillance systems in Spain were transformed into a new syndromic sentinel surveillance system. The Acute Respiratory Infection Surveillance System (SiVIRA in Spanish) is based on a sentinel network for acute respiratory infection (ARI) surveillance in primary care and a network of sentinel hospitals for severe ARI (SARI) surveillance in hospitals.

METHODS:

Using a test-negative design and data from SARI admissions notified to SiVIRA between January 1 and October 3, 2021, we estimated COVID-19 vaccine effectiveness (VE) against hospitalization, by age group, vaccine type, time since vaccination, and SARS-CoV-2 variant.

RESULTS:

VE was 89% (95% CI 83-93) against COVID-19 hospitalization overall in persons aged 20 years and older. VE was higher for mRNA vaccines, and lower for those aged 80 years and older, with a decrease in protection beyond 3 months of completing vaccination, and a further decrease after 5 months. We found no differences between periods with circulation of Alpha or Delta SARS-CoV-2 variants, although variant-specific VE was slightly higher against Alpha.

CONCLUSIONS:

The SiVIRA sentinel hospital surveillance network in Spain was able to describe clinical and epidemiological characteristics of SARI hospitalizations and provide estimates of COVID-19 VE in the population under surveillance. Our estimates add to evidence of high effectiveness of mRNA vaccines against severe COVID-19 and waning of protection with time since vaccination in those aged 80 or older. No substantial differences were observed between SARS-CoV-2 variants (Alpha vs. Delta).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Tract Infections / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Europa Language: English Journal: Influenza Other Respir Viruses Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: Irv.13026

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Tract Infections / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Europa Language: English Journal: Influenza Other Respir Viruses Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: Irv.13026